Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100


5'-Phosphate and 5'-phosphonate ester derivatives of (N)-methanocarba adenosine with in vivo cardioprotective activity.

Kumar TS, Yang T, Mishra S, Cronin C, Chakraborty S, Shen JB, Liang BT, Jacobson KA.

J Med Chem. 2013 Feb 14;56(3):902-14. doi: 10.1021/jm301372c. Epub 2013 Jan 22.


Structure-activity relationship of (N)-Methanocarba phosphonate analogues of 5'-AMP as cardioprotective agents acting through a cardiac P2X receptor.

Kumar TS, Zhou SY, Joshi BV, Balasubramanian R, Yang T, Liang BT, Jacobson KA.

J Med Chem. 2010 Mar 25;53(6):2562-76. doi: 10.1021/jm9018542.


Treatment of heart failure by a methanocarba derivative of adenosine monophosphate: implication for a role of cardiac purinergic P2X receptors.

Zhou SY, Mamdani M, Qanud K, Shen JB, Pappano AJ, Kumar TS, Jacobson KA, Hintze T, Recchia FA, Liang BT.

J Pharmacol Exp Ther. 2010 Jun;333(3):920-8. doi: 10.1124/jpet.109.164376. Epub 2010 Mar 3.


P2X purinergic receptor-mediated ionic current in cardiac myocytes of calsequestrin model of cardiomyopathy: implications for the treatment of heart failure.

Shen JB, Cronin C, Sonin D, Joshi BV, Gongora Nieto M, Harrison D, Jacobson KA, Liang BT.

Am J Physiol Heart Circ Physiol. 2007 Feb;292(2):H1077-84. Epub 2006 Oct 13.


The A3 adenosine receptor attenuates the calcium rise triggered by NMDA receptors in retinal ganglion cells.

Zhang M, Hu H, Zhang X, Lu W, Lim J, Eysteinsson T, Jacobson KA, Laties AM, Mitchell CH.

Neurochem Int. 2010 Jan;56(1):35-41. doi: 10.1016/j.neuint.2009.08.011. Epub 2009 Aug 31.


Northern Ring Conformation of Methanocarba-Adenosine 5'-Triphosphate Required for Activation of P2X Receptors.

Dunn PM, Kim HS, Jacobson KA, Burnstock G.

Drug Dev Res. 2004 Apr;61(4):227-232. Epub 2004 Sep 22.


Induction of novel agonist selectivity for the ADP-activated P2Y1 receptor versus the ADP-activated P2Y12 and P2Y13 receptors by conformational constraint of an ADP analog.

Chhatriwala M, Ravi RG, Patel RI, Boyer JL, Jacobson KA, Harden TK.

J Pharmacol Exp Ther. 2004 Dec;311(3):1038-43. Epub 2004 Sep 2.


Synthesis and characterization of [76Br]-labeled high-affinity A3 adenosine receptor ligands for positron emission tomography.

Kiesewetter DO, Lang L, Ma Y, Bhattacharjee AK, Gao ZG, Joshi BV, Melman A, de Castro S, Jacobson KA.

Nucl Med Biol. 2009 Jan;36(1):3-10. doi: 10.1016/j.nucmedbio.2008.10.003.


The A3 adenosine receptor agonist CP-532,903 [N6-(2,5-dichlorobenzyl)-3'-aminoadenosine-5'-N-methylcarboxamide] protects against myocardial ischemia/reperfusion injury via the sarcolemmal ATP-sensitive potassium channel.

Wan TC, Ge ZD, Tampo A, Mio Y, Bienengraeber MW, Tracey WR, Gross GJ, Kwok WM, Auchampach JA.

J Pharmacol Exp Ther. 2008 Jan;324(1):234-43. Epub 2007 Sep 28.


Glyburide-reversible cardioprotective effects of BMS-180448: functional and energetic considerations.

Grover GJ, Sleph PG, Dzwonczyk S, Malone HJ, Behling RW.

J Cardiovasc Pharmacol. 1997 Jan;29(1):28-38.


Adenosine-A1 receptors activation restores the suppressed cardioprotective effects of ischemic preconditioning in hyperhomocysteinemic rat hearts.

Balakumar P, Singh H, Reddy K, Anand-Srivastava MB.

J Cardiovasc Pharmacol. 2009 Sep;54(3):204-12. doi: 10.1097/FJC.0b013e3181b04cc5.


Synthesis and pharmacological characterization of [(125)I]MRS1898, a high-affinity, selective radioligand for the rat A(3) adenosine receptor.

Gao ZG, Teng B, Wu H, Joshi BV, Griffiths GL, Jacobson KA.

Purinergic Signal. 2009 Mar;5(1):31-7. doi: 10.1007/s11302-008-9107-1. Epub 2008 Jun 5.


Synthesis and pharmacological characterization of [(125)I]MRS5127, a high affinity, selective agonist radioligand for the A3 adenosine receptor.

Auchampach JA, Gizewski ET, Wan TC, de Castro S, Brown GG Jr, Jacobson KA.

Biochem Pharmacol. 2010 Apr 1;79(7):967-73. doi: 10.1016/j.bcp.2009.11.009. Epub 2009 Nov 14.


Cl-IB-MECA [2-chloro-N6-(3-iodobenzyl)adenosine-5'-N-methylcarboxamide] reduces ischemia/reperfusion injury in mice by activating the A3 adenosine receptor.

Ge ZD, Peart JN, Kreckler LM, Wan TC, Jacobson MA, Gross GJ, Auchampach JA.

J Pharmacol Exp Ther. 2006 Dec;319(3):1200-10. Epub 2006 Sep 19.


Novel l-adenosine analogs as cardioprotective agents.

Kasiganesan H, Wright GL, Chiacchio MA, Gumina G.

Bioorg Med Chem. 2009 Jul 15;17(14):5347-52. doi: 10.1016/j.bmc.2008.12.011. Epub 2008 Dec 14.


Structural determinants of A(3) adenosine receptor activation: nucleoside ligands at the agonist/antagonist boundary.

Gao ZG, Kim SK, Biadatti T, Chen W, Lee K, Barak D, Kim SG, Johnson CR, Jacobson KA.

J Med Chem. 2002 Sep 26;45(20):4471-84.


Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure.

Gundewar S, Calvert JW, Jha S, Toedt-Pingel I, Ji SY, Nunez D, Ramachandran A, Anaya-Cisneros M, Tian R, Lefer DJ.

Circ Res. 2009 Feb 13;104(3):403-11. doi: 10.1161/CIRCRESAHA.108.190918. Epub 2008 Dec 18.


A beneficial role of cardiac P2X4 receptors in heart failure: rescue of the calsequestrin overexpression model of cardiomyopathy.

Yang A, Sonin D, Jones L, Barry WH, Liang BT.

Am J Physiol Heart Circ Physiol. 2004 Sep;287(3):H1096-103. Epub 2004 May 6.

Supplemental Content

Support Center